RenovoRx’s TAMP Therapy Shows Reduced Toxicity in Pancreatic Cancer Trial
Event summary
- RenovoRx presented clinical data at the 2026 SIR Annual Scientific Meeting showing TAMP therapy reduced systemic toxicity in locally advanced pancreatic cancer (LAPC) patients.
- Metabolic imaging (FDG PET/CT) revealed significant tumor activity reduction after eight cycles of intra-arterial chemotherapy via TAMP.
- The study was conducted by Moffitt Cancer Center experts, including Dr. Mustafa Al-Roubaie, a member of RenovoRx’s Medical Advisory Board.
- RenovoRx’s RenovoCath device enabled the targeted drug delivery, supporting its potential for commercial expansion.
The big picture
RenovoRx’s TAMP therapy platform represents a strategic shift in pancreatic cancer treatment, leveraging targeted drug delivery to overcome the limitations of systemic chemotherapy. The positive clinical data supports its potential to reduce toxicity while improving efficacy, aligning with broader industry trends toward precision oncology. The company’s ability to commercialize RenovoCath and advance its Phase III trial will determine its long-term competitive positioning in the oncology market.
What we're watching
- Commercialization Momentum
- Whether RenovoRx can sustain revenue growth from RenovoCath sales, which reached $1.1 million in 2025, amid expanding institutional adoption.
- Regulatory Pathway
- The pace at which the Phase III TIGeR-PaC trial progresses, as it is critical for securing FDA approval for the IAG combination product.
- Competitive Positioning
- How RenovoRx differentiates TAMP therapy in the crowded oncology space, particularly against systemic chemotherapy alternatives.
Related topics